Back

Lipoprotein(a) lowering and risk of cardiovascular disease in primary and secondary prevention

29 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Lipoproteins and coronary artery disease (1) Lipids ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Pia Kamstrup

Copenhagen University Hospital, Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Prevalence and impact of a pathogenic CYP27A1 variant on phenotypes among patients with monogenic heterozygous familial hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides
Presentation thumbnail
Apolipoprotein b discordance at very low low-density lipoprotein cholesterol thresholds: a patient-level analysis
Doctor J. Bernhard (Vienna, AT)
Abstract Slides
Presentation thumbnail
Nationwide genotypic and phenotypic characterisation of homozygous familial hypercholesterolemia
Doctor C. Lin (Taipei, TW)
Abstract Slides
Presentation thumbnail
Clinical impact of more than 50% reduction in low-density lipoprotein cholesterol at 6 weeks after percutaneous coronary intervention for acute coronary syndrome
Doctor K. Murai (Osaka, JP)
Abstract Slides
Presentation thumbnail
Prevalence of elevated lipoprotein(a) [Lp(a)] in patients with familial hypercholesterolemia (FH)
Doctor J. Sawhney (New Delhi, IN)
Abstract Slides

Access the full session

Session thumbnail
Lipoproteins and coronary artery disease (1)

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
28 August 2020
thumbnail
Congress Presentation
Effect of blood pressure reduction on cardiovascular outcomes in patients with different baseline cardiovascular risk: systematic review and meta-analysis of randomized trials
28 August 2022
thumbnail
Congress Presentation
Boosting secondary prevention: efficacy and adherence of inclisiran in post-acute coronary syndrome very high-risk patients
3 April 2025
thumbnail
Congress Presentation
High lipoprotein(a) and high BMI jointly confer the highest risk of ASCVD in both primary and secondary prevention
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources